Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,197.51 +16.77 (+0.32%) Dow
38,928.03 +75.76 (+0.20%) Nasdaq
16,384.57 +35.33 (+0.22%) Bitcoin USD
63,515.22 +147.50 (+0.23%) CMC Crypto 200
1,316.01 -49.12 (-3.60%)
Armata Pharmaceuticals Inc (TG1N.MU)
| Previous close | 2.3000 |
| Open | 2.3000 |
| Bid | 2.5400 x N/A |
| Ask | 2.7200 x N/A |
| Day's range | 2.3000 - 2.3000 |
| 52-week range | 1.0300 - 4.2400 |
| Volume | |
| Avg. volume | 60 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2023, and provided a corporate update.
- PR Newswire
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C
- PR Newswire
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston.
